Board of Directors

Board of Directors

Ahryon Cho, PhD | Investment Division / General Manager, Mirae Asset

Ahryon Cho is a general manager at Mirae Asset Venture Investment (MAVI) based in Korea, and MAVI is the venture capital arm of Mirae Asset group that is one of the renowned, largest financial service group in Asia. Since joining Mirae Asset group in 2016, she has completed multiple equity investments in companies developing innovative therapeutics and diagnostics, and been serving the board of directors of her portfolio companies.

Prior to joining Mirae Asset group, she was a research assistant professor at Yonsei University School of Medicine from 2014 to 2016. She received her Ph.D. in Molecular Biology and Neuroscience at Princeton University, NJ, USA, and completed her post-doctoral training in Pathology at Stanford University School of Medicine, CA, USA. One of her post-doctoral researches resulted in the foundation of a biotech company based in CA, USA that is currently in pre-clinical stage.

Andrew Khoo | Chief Executive Officer & Co-Founder, Tessa Therapeutics

Andrew Khoo is the CEO and Co-founder of Tessa therapeutics, an international biotechnology company specialized in virus-associated cancer immunotherapy.  Tessa’s core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors such as nose, cervical, liver, lung, and stomach cancer. Under Mr. Khoo’s leadership, Tessa has grown to become a 100+ employee company, with operations across 5 countries, and is also currently running the world’s largest phase 3 adoptive T cell therapy trial for any cancer indication.

An active investor in healthcare and technology focused start-ups, Mr. Khoo is also a Director of other leading biotechnology companies such as Euchloe Bio and Enleofen Bio, that specialize in the development and commercialization of antibodies to treat cancer and fibrotic diseases, respectively.

Prior to his involvement with Tessa, Mr. Khoo worked in various roles at global investment banks including JP Morgan and Citigroup. He began his career at the Singapore Economic Development Board after graduating from Stanford University on a full government scholarship.

Glen N. Barber, PhD | Co-Founder and Director, Vyriad

Glen Barber is Professor (2008-present) and Chairman (2011-present) of the Department of Cell Biology, Associate Director for Basic Research, and Eugenia Dodson Chair in Cancer Research of the Sylvester Comprehensive Cancer Center (2006-present) at the University of Miami Miller School of Medicine, Florida. He is an internationally recognized scientist in the field of innate immune defense and antiviral strategies, with more than 150 scientific publications, many in high-profile journals such as Nature, Science, and Cell. Since joining the University of Miami in 1999, Dr. Barber has been developing novel vesicular stomatitis virus (VSV) therapeutics and led cutting-edge research in understanding the mechanisms of innate immunity to viral infection and malignant disease, including the recent discovery of STING and the elucidation of its role in innate immunity. He is also the CEO and President of STINGINN, a company he founded based on his STING technology. Dr. Barber received his PhD in Molecular Virology at London University, England.

Stephen J. Russell, MD, PhD | Founder, Director, CEO and President, Vyriad

Dr Russell is the CEO of Vyriad.  He is also the Richard O Jacobson Professor of Molecular Medicine at Mayo Clinic and Vice President of the American Society of Gene and Cell Therapy.  He obtained his MD from the University of Edinburgh in 1982 and since that time has relentlessly pursued the goal of effective oncolytic virotherapy.  He specialized clinically in hematology, then undertook his PhD training at the Royal Marsden hospital where he was the first to engineer both retroviral and parvoviral vectors to deliver interleukin genes for cancer immunotherapy. He then moved to Cambridge, England where he led a research team in the MRC Laboratory for Molecular Biology, developed a novel method for antibody affinity maturation using phage display libraries, pioneered the display antibody domains on retroviral vector particles and on recombinant measles viruses, and founded Cambridge Genetics, a biotechnology/drug discovery company. In 1998 he moved to Mayo Clinic where he founded the Department of Molecular Medicine, built a comprehensive oncolytic virotherapy program, developed innovative engineering approaches for targeting, arming and noninvasively monitoring OV infections, and orchestrated the GMP manufacture, preclinical pharmacological/toxicological testing, IND filing and clinical translation of a number of oncolytic Measles and Vesicular stomatitis viruses for several different cancer indications.   He cofounded two oncolytic virotherapy companies which merged in 2015, thereby establishing Vyriad as the first multi-platform OV company.